Naseem Amin is Director at Bellerophon Therapeutics, Inc. (BLPH). They have made 1 open-market trade across 1 company since 2016, most recently 2026-02-12.
CIK 0001646754
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $800K since 2016, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BLPH | BUY | 2019-01-25 | 2019-01-25 | $0.70 | $800K | -1.9% | -5.1% | -11.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.